Request Demo

Last update 07 Jul 2025

Carbidopa/Levodopa

Last update 07 Jul 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

AP-CD/LD, AP-CDLD, Carbidopa and Levodopa

+ [63]

Target

DDC x DRDs

Action

inhibitors, antagonists

Mechanism

DDC inhibitors(DOPA decarboxylase inhibitors), DRDs antagonists(Dopamine receptors antagonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Parkinsonian DisordersParkinson DiseaseParkinson Disease, Postencephalitic+ [5]

Inactive Indication

ComplicationNeuroleptic Malignant SyndromePsychomotor Agitation

Originator Organization

Merck & Co., Inc.

Active Organization

Bdd Pharma Ltd

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Impax Laboratories LLC

+ [17]

Inactive Organization

Hong Kong WD Pharmaceutical Co., Ltd.Amneal Pharma Europe Ltd.

Shanghai WD Pharmaceutical Co. Ltd.

+ [1]

License Organization

Amneal Intermediate, Inc.

Navamedic ASA

Contera Pharma ApS

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (02 May 1975),

Parkinson Disease, PostencephaliticParkinson Disease, SecondaryParkinson Disease

RegulationFast Track (United States), Orphan Drug (United States)

178

Clinical Trials associated with Carbidopa/Levodopa

NCT07001150

/ RecruitingPhase 2IIT

Clinical Study Evaluating the Possible Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.

Start Date30 Jun 2025

Sponsor / Collaborator

Tanta University

NCT06831500

/ Not yet recruitingPhase 1/2IIT

A Monocentric, Randomized, Double-blind Study to Assess the Feasibility of Conducting a Full-scale Randomized Controlled Trial (RCT) Assessing the Effect of Carbidopa/levodopa Ratio on Orthostatic Hypotension (OH) in Multiple System Atrophy - Parkinsonian Type (MSA-P) and Parkinson Disease (PD) Patients (CARBIDOH)

This study is aimed at patients with multi-system atrophy - parkinsonian type (P-MSA) or Parkinson's disease (PD) receiving dopaminergic drugs and suffering from orthostatic hypotension (OH).
OH is a drop in blood pressure when standing, which can lead to symptoms of dizziness, lightheadedness, a black veil in front of the eyes and, when severe, can lead to fainting. HO is one of the symptoms present in AMS-P and PD.
The standard treatment for parkinsonian symptoms of slowness and stiffness is the administration of antiparkinsonian drugs containing dopamine. These dopaminergic drugs always contain 1) levodopa (which is the precursor of dopamine) and 2) an enzyme inhibitor, which may be either benserazide (in the case of Madopar® and its generics) or carbidopa (in the case of Sinemet® or Stalevo® and their generics) and whose role is to potentiate the effect of levodopa.
It has long been known that dopaminergic drugs aggravate HO. Through various mechanisms, this worsening of HO is linked as much to levodopa as to the enzyme inhibitor with which it is combined. However, investigators do not know the respective effects of these two molecules on HO.
In this study, investigators examine how the ratio of Carbidopa to levodopa affects HO in the various assays of the dopaminergic drug under study.

Start Date01 May 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire Vaudois

NCT06765668

/ RecruitingPhase 4

Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients

The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

Start Date12 Feb 2025

Sponsor / Collaborator

Impax Laboratories LLC

[+1]

100 Clinical Results associated with Carbidopa/Levodopa

100 Translational Medicine associated with Carbidopa/Levodopa

100 Patents (Medical) associated with Carbidopa/Levodopa

761

Literatures (Medical) associated with Carbidopa/Levodopa

03 Jun 2025·Expert Review of Medical Devices

The device-aided intrajejunal delivery of levodopa–entacapone–carbidopa intestinal gel the treatment of Parkinson’s disease: overview of efficacy and safety

Review

Author: Popławska-Domaszewicz, Karolina ; Metta, Vinod ; Odin, Per ; Chaudhuri, K Ray

INTRODUCTION:

Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while levodopa-entacapone-carbidopa intestinal gel (LECIG), delivered via the Crono LECIG pump, is a more recent addition to the range of DAT options in Europe.

AREAS COVERED:

This article explores the rationale for the development of LECIG infusion, the role of entacapone in the formulation, and the attributes and specifications of the LECIG infusion pump device. Clinical and real-world data reporting its efficacy, safety and tolerability of LECIG in advanced PD patients from a range of European centers are reviewed, with a focus on the practical benefits that a smaller, lighter and quieter device can provide for patients who wish to start treatment with intrajejunal levodopa infusion.

EXPERT OPINION:

LECIG infusion delivered via the LECIG infusion pump offers another valuable DAT option to consider for suitable people with advanced PD providing both good long-term clinical benefits and a favorable treatment experience for patients.

01 Jun 2025·CNS DRUGS

Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson’s Disease

Review

Author: Blair, Hannah A

Foslevodopa/foscarbidopa [PRODUODOPA^® (EU); VYALEV^™ (USA, Canada, Japan)] is a soluble formulation of levodopa and carbidopa prodrugs for 24-h continuous subcutaneous (SC) infusion. It is approved for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). Administered via an ambulatory infusion pump, it allows for personalized dosing based on individual needs. In a randomized, double-blind, double-dummy trial, continuous SC infusion of foslevodopa/foscarbidopa provided a significant and clinically meaningful increase in hours of 'on' time without troublesome dyskinesia and a reduction in hours of 'off' time compared with oral immediate-release levodopa/carbidopa. The benefits of foslevodopa/foscarbidopa were maintained over the longer term (up to 124 weeks). Continuous SC infusion of foslevodopa/foscarbidopa was generally well tolerated, including over the longer term. However, infusion site events were common, necessitating regular monitoring, cannula replacement, infusion site rotation and aseptic techniques. Although further long-term data are required, foslevodopa/foscarbidopa represents a promising non-surgical alternative to the available device-aided therapies for patients with advanced PD whose motor fluctuations are inadequately controlled by other oral PD medications.

04 May 2025·Neurodegenerative Disease Management

Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study

Article

Author: Daghi, Mohamed ; Lakhdar, Abdelhakim ; El Otmani, Hicham ; Serhier, Zineb

AIM:

This study investigates the prevalence and clinical features of advanced Parkinson's disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG).

METHODS:

We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility.

RESULTS:

This study included 370 patients with Parkinson's disease, of whom 44.6% (95%CI: 39.5%-49.8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1.08, p = 0.047). Overall, 38.9% of patients qualified for at least one DAT, including 18.9% for DBS, 35.4% for CSAI, and 13.8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0.93, p < 0.001). Additionally, premotor REM sleep behavior disorder increased the odds of LCIG eligibility (ORa = 2.38, p = 0.009), while prior sports engagement nearly tripled the odds for CSAI (ORa = 2.87, p = 0.038).

CONCLUSION:

Although many Moroccan patients qualify for DATs, their use is minimal. Addressing access barriers is crucial to improve outcomes.

141

News (Medical) associated with Carbidopa/Levodopa

27 Jun 2025

·www.prnewswire.com

Navamedic ASA: First approval of the medical device OraFID® as primary package for a pharmaceutical product

OSLO, Norway, June 27, 2025 /PRNewswire/ -- Navamedic announces that the Swedish Medical Products Agency, acting as the Reference Member State, together with the Concerned Member States in 9 additional countries have approved OraFID® for use with a medicinal product. "OraFID® is a unique, fully mechanical medical device that dispenses precise quantities of minitablets to patients. It enables personalized, fine-tuned treatment with minitablets, and I am thrilled to see the approval of this important milestone." says Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic. Treatments with a narrow therapeutic window can benefit from hyper-fractioning of the dose, by dividing it into minitablets, each containing a fraction of the dose. OraFID® works with a couple of twists of the hands and ejects an exact number of minitablets. It is approved as an integral combination product for Flexilev®, Navamedic's medication for the treatment of Parkinson's. The launch in Nordic markets is anticipated in October 2025. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880 E-mail: [email protected] Lars Hjarrand, CFO, Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit Navamedic.com This information was brought to you by Cision Navamedic ASA: First approval of the medical device OraFID® as primary package for a pharmaceutical product Oslo, Norway - 2025.06.27 - Navamedic announces that the Swedish Medical Products Agency, acting as News Powered by Cision WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

20 Jun 2025

·www.prnewswire.com

Mitsubishi Tanabe Pharma America Highlights Parkinson's Disease Research at 2025 EAN and ATMRD Congresses

JERSEY CITY, N.J., June 20, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced poster presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the 11th Congress of the European Academy of Neurology (EAN), taking place June 21-24 in Helsinki, Finland, and the 4th Annual Advanced Therapeutics in Movement & Related Disorders Congress (ATMRD), being held June 27-30 in Washington D.C. ND0612 is being evaluated as a 24-hour, continuous, subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD). "Being part of both EAN and ATMRD gives us the opportunity to engage with the broader neurology community, while spotlighting a range of data on ND0612 across two key scientific forums," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. "Our presence at these meetings reflects our dedication to supporting scientific exchange and sharing insights from our latest research focused on evaluating motor fluctuations in Parkinson's disease." EAN 2025 Presentation Details MTPA will be presenting one e-poster describing the effect of treatment with ND0612 on OFF and ON episodes, their duration, and transitions, in people experiencing motor fluctuations, as observed from the pivotal Phase 3 BouNDless study (NCT04006210) and its one-year open-label extension (OLE) phase. Effect of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (Investigational ND0612) on Motor Fluctuations in the Phase 3 BouNDless Study (Joaquim J. Ferreira, M.D., Ph.D.; University of Lisbon) ePoster #EPR-052, Movement Disorders 1 Session: 2:35-2:40 p.m. EEST, June 21 ATMRD 2025 Presentation Details Presentations will detail findings from the Phase 3 BouNDless trial, including data derived from patient-reported outcomes assessing quality of life in people with PD experiencing motor fluctuations who are being treated with ND0612, as well as one-year outcomes from the BouNDless OLE phase. Additionally, a poster describing the characterization of dopaminergic treatment-emergent adverse events (AEs) reported in ND0612-treated patients will be shared. MTPA's posters will be viewable in the Exhibit Hall on June 27, 11:30 a.m.-12:20 p.m. EDT. Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of Investigational ND0612 (Huyen Phan, Pharm.D.; MTPA) Poster #P42 Quality of Life With 24-hour subcutaneous Levodopa/Carbidopa Infusion (Investigational ND0612): QoL Results from a Phase 3, Randomized, Active-Controlled Study (Amanda Goldberg, MPAS, PA-C; MTPA) Poster #P412 Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (Investigational ND0612) for Motor Fluctuations in Parkinson's Disease (Rajesh Pahwa, M.D., FAAN; University of Kansas Medical Center) Poster #P32 About ND0612 ND0612 is an investigational drug-device combination therapy – a 24-hour, continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations in people with Parkinson's disease (PD). Development of investigational ND0612 is being led by NeuroDerm Ltd., a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit or follow us on X (formerly Twitter), Facebook and LinkedIn. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation (MTPC) is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to About NeuroDerm Ltd. NeuroDerm Ltd. is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), based in Israel, inspired to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at or follow the Company on LinkedIn. Media inquiries: [email protected] SOURCE Mitsubishi Tanabe Pharma America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3

07 May 2025

·www.prnewswire.com

Mitsubishi Tanabe Pharma America Announces Presentations at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD)

JERSEY CITY, N.J., May 7, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that two poster presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD) to be held May 7-10 in New York City. ND0612 is being evaluated as a 24-hour, continuous, subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD). "We are pleased to present our ongoing research evaluating ND0612 in Parkinson's disease at IAPRD," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. "This continued work reflects our dedication to expanding our knowledge of PD and sharing key study insights with the broader patient and scientific communities." MTPA's posters will be viewable in the Exhibit and Poster Hall throughout the meeting and presented during the Guided Poster Tour on Saturday, May 10, from 8:00 a.m. to 9:00 a.m. EDT. Presentation Details: Presentations will highlight findings from the pivotal Phase 3 BouNDless trial (NCT04006210), evaluating ND0612 in individuals with PD experiencing motor fluctuations. The data presented will include patient-reported outcomes assessing motor experiences of daily living, as well as the impact of 24-hour treatment with ND0612 on motor state transitions, based on patient home diaries. Effect of ND0612 Continuous Infusion on Motor Performance and Experiences of Daily Living in Patients with Parkinson's Disease (Rebecca Vayalumkal, PharmD, RPh; MTPA) Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Daily Motor State Characteristics of Patients with Parkinson's Disease Experiencing Motor Fluctuations (Rebecca Vayalumkal, PharmD, RPh; MTPA) About ND0612 ND0612 is an investigational drug-device combination therapy – a 24-hours/day, continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations in people with Parkinson's disease (PD). Development of investigational ND0612 is being led by NeuroDerm, Ltd., a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit or follow us on X (formerly Twitter), Facebook and LinkedIn. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation (MTPC) is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to About NeuroDerm, Ltd. NeuroDerm, Ltd. is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), based in Israel, inspired to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at or follow the Company on LinkedIn. Media inquiries: [email protected] SOURCE Mitsubishi Tanabe Pharma America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3

100 Deals associated with Carbidopa/Levodopa

External Link

KEGG	Wiki	ATC	Drug Bank
-	Carbidopa/Levodopa	N04BA02	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Parkinsonian Disorders	Japan	Tatsumi Kagaku Co., Ltd.	14 May 1993
Parkinson Disease	United States	Organon & Co.	02 May 1975
Parkinson Disease, Postencephalitic	United States	Organon & Co.	02 May 1975
Parkinson Disease, Secondary	United States	Organon & Co.	02 May 1975

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dyskinesias	Phase 3	United States	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	Finland	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	Greece	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	Hungary	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	Italy	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	Slovakia	AbbVie, Inc.	09 Feb 2017
Dyskinesias	Phase 3	Spain	AbbVie, Inc.	09 Feb 2017
Neuroleptic Malignant Syndrome	Phase 3	United States	AbbVie, Inc.	26 Oct 2015
Neuroleptic Malignant Syndrome	Phase 3	Australia	AbbVie, Inc.	26 Oct 2015
Neuroleptic Malignant Syndrome	Phase 3	Canada	AbbVie, Inc.	26 Oct 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06219915 (RES, CTgov)	Phase 1/2	Parkinsonian Disorders	13	Carbidopa 25 mg+Carbidopa-Levodopa 25/100 mg (Carbidopa Monotherapy and Carbidopa-Levodopa)	juywlvdxaf(muhjwuniei) = qhghzpuolm nvjregomuh (tbsimuouvt, 0.14) View more	-	17 Jun 2025
NCT06219915 (RES, CTgov)	Phase 1/2	Parkinsonian Disorders	13	Placebo 1 (Placebo)	juywlvdxaf(muhjwuniei) = agcbtduwjr nvjregomuh (tbsimuouvt, 0.18) View more	-	17 Jun 2025
RISE-PD (AAN2025)	Phase 3	Parkinson Disease levodopa-equivalent-daily-dose (LEDD) of DA	-	CREXONT	dmrwdcywuh(uxsqtnvajf) = qruboatbdy ppvxrrlyol (lcgyjgokdq )	Positive	07 Apr 2025
RISE-PD (AAN2025)	Phase 3		-	Dopamine agonist LEDD ≤200mg	dmrwdcywuh(uxsqtnvajf) = rebwybiliq ppvxrrlyol (lcgyjgokdq )	Positive	07 Apr 2025
P11-5.010 (AAN2025)	Phase 3	-	495	CREXONT	ufynedhsyn(ezziezkmwe) = welcwhcfld zihfsjwiua (cmqrcidsrl )	Positive	07 Apr 2025
P11-5.010 (AAN2025)	Phase 3	-	495	Immediate-Release Carbidopa-Levodopa (IR CD-LD)	ufynedhsyn(ezziezkmwe) = eevhjelbil zihfsjwiua (cmqrcidsrl )	Positive	07 Apr 2025
NCT04006210 (BouNDless, PRNewswire) Manual	Phase 3	Parkinson Disease	-	ND0612	kxbfvxxkru(sziiflzenm) = zbajxxvyvh amfmshuina (byxjhekltz ) View more	Positive	30 Sep 2024
NCT03670953 (FDA_CDER) Manual	Phase 3	Parkinson Disease	630	CREXONT	yvjwmovtty(ohbxgvuxvz) = jmaigreyxy srcjgzgdoe (kdyazyfsly ) View more	Positive	07 Aug 2024
NCT03670953 (FDA_CDER) Manual	Phase 3	Parkinson Disease	630	Immediate-release carbidopa-levodopa	yvjwmovtty(ohbxgvuxvz) = ycsaxwqase srcjgzgdoe (kdyazyfsly ) View more	Positive	07 Aug 2024
NCT02577523 (Phase 2 study, EAN2024)	Phase 2	Parkinson Disease	19	24h ND0612 infusion	liqhbyhovg(zdiyiispcg) = 73.7% of patients self-reported an improvement (including 36.8% very much/much improved) in their global impression of health on Day 3 mecdslnwvo (rrsamhgvcd )	Positive	28 Jun 2024
NCT04006210 (Phase 3 study, EAN2024)	Phase 3	Parkinson Disease	-	Levodopa/carbidopa infusion (ND0612)	jfqbfwkmbz(vpndgyrahd) = Occurrence of adverse events (AEs) and serious AEs were generally consistent across subgroups (age, gender, region, and BMI). Consistent with the data for the full safety population, the most common AEs with ND0612 treatment across all subgroups were infusion site reactions. Overall, no relevant differences between subgroups were observed for AEs of particular interest, including dyskinesia, hallucinations, or falls. gdmxyttssp (kiirqfkziy )	Positive	28 Jun 2024
EAN2024	Not Applicable	Injection Site Reaction	-	ND0612	dyidqcklws(qizfrmqrxa) = Most (88.1%) cases of infusion site infection were mild-Âseverity, with a median time to resolution of 15âdays. Infusion site infection led to discontinuation in only 12 (2.9%) patients. dmfuhanyxd (tuvwamdizm )	-	28 Jun 2024
AAN2024	Not Applicable	Parkinson Disease	-	24-hour ND0612 infusion	mhkqiipdyz(brsvcqpvfj) = mriqhoekpl hfxipkygnd (nxbyehbvys ) View more	-	09 Apr 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis